• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aurinia Pharm Ord (NQ: AUPH )

    7.435 +0.155 (+2.13%)
    Streaming Delayed Price Updated: 10:41 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aurinia Pharm Ord

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Announces Board Restructuring
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia to Participate in Upcoming Investor Healthcare Conferences
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Announces 2024 Annual General Meeting Results
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Provides Update on Proxy Statement
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia to Participate in Upcoming Investor Healthcare Conferences
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
    Via Benzinga
    Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
    Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
    Via Benzinga
    Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.